Document is current
Any future updates will be listed below
-
Authors
Thorarinsson, Bjorn Logi https://orcid.org/0009-0004-0576-5990
Sveinsson, Olafur Arni https://orcid.org/0000-0002-4507-2935
Hilmarsson, Agust
Sigurthorsdottir, Thora Bjorg
Andersen, Peter Munch https://orcid.org/0000-0003-0094-5429
- License Information
-
More Information
Article History
Received: 17 October 2025
Revised: 9 December 2025
Accepted: 12 December 2025
First Online: 11 February 2026
Declarations
:
: Author PMA: Paid consultancies and serves/have served on advisory boards/expert testimony boards for EMA (European Medicines Agency), Biogen, Arrowhead, Avrion, Mitsubishi Pharma, Regeneron, uniQure and Orphazyme A/S; PMA is clinical trial site investigator for AB Science, AL-S Pharma and Lilly, Amylyx Pharmaceuticals, Alexion Pharmaceuticals, Biogen, IONIS Pharmaceuticals, ITB-Med, Novartis, Orion Pharma, PTH Pharmaceuticals, Sanofi, uniQure Biopharma, Zydus Therapeutics. Since 1993, Director of the ALSgenetic laboratory at Umeå University Hospital that performs not-for-profit research genetic testing. Since 2021, member of the ClinGen ALS Gene variant Curation Expert panel. PMA report grants from the Swedish Research Council, the Knut and Alice Wallenberg Foundation, the Ulla-Carin Lindquist Foundation, NEURO, the Brain Foundation and the Fort Knox Charity Foundation and the Olsson & Olsson Charity Foundation; as well as consulting fees from Biogen, Avrion, Arrowhead, Regeneron, uniQure, Orphazyme and Roche. None of the other authors has any financial disclosures or conflicts to report.
